On September 16, the Huntington’s disease community received the news they have been waiting for. Roche & Genentech: one company, two names, announces its plans to begin the clinical trial on the drug RG6042 (formerly known as IONIS_HTTRx).
The Ionis-HTTRx drug is an antisense therapy. It targets messenger RNA, a molecule that is an intermediary between DNA, the cell’s genetic material, and the huntingtin protein. Cells use the message as a template to produce the protein. It is designed to stick to a faulty HTT gene’s messenger RNA, reducing the amount of abnormal huntingtin protein the gene generates.
Huntington’s disease (HD) is like having Alzheimer’s, Parkinson’s and ALS at the same time. There is NO CURE and it affects children and adults.
Update on RG6042 (formerly known as IONIS-HTTRx)
Huntington’s disease global development programme: Two clinical studies to begin by end of 2018
Dear Global Huntington’s Community,
Thank you for your ongoing support and interest in the investigational medicine RG6042 for Huntington’s disease (HD).
Over the past months we and our partner Ionis Pharmaceuticals have been heavily engaged with communities around the world (patient groups, medical professionals, Health Authorities and payers) to collaborate and build the RG6042 global development programme and upcoming studies. We are eager for RG6042 to advance into further clinical development. In addition, as announced last month, the European Medicines Agency granted RG6042 PRIME (“PRIority MEdicine”) designation, which provides promising medicines enhanced interactions with the agency and the potential for accelerated evaluation. Read the full article here
Article from HDBuzz.net Roche announces details of its ‘pivotal’ huntingtin lowering study
Article from huntingtonsdiseasenews.com https://huntingtonsdiseasenews.com/2018/09/24/roche-announces-2-clinical-studies-potential-huntingtons-therapy-rg6042/
Author Therese Crutcher-Marin
We Can Never Lose Hope……….